GSK (GSK)

Sector:

Pharma and Biotech

Index:

FTSE 100

1,311.50p
   
  • Change Today:
      11.50p
  • 52 Week High: 1,812.50p
  • 52 Week Low: 1,300.00p
  • Currency: UK Pounds
  • Shares Issued: 4,145.10m
  • Volume: 1,231,408
  • Market Cap: £54,363m
  • RiskGrade: 129
  • Beta: 0.56

GSK Overview

We are a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people by the end of 2030. Our bold ambitions for patients are reflected in commitments to growth and a step-change in performance. We are a company where outstanding people can thrive.

1 Day Chart

1 Day Chart

6 Month Chart

6 Month Chart
Barclays logo

Digital Look Charts Sponsored by Barclays Stockbrokers

Financials

Latest F'cast
Div Yield 0.9% 0.0%
Div Cover n/a 2.6
Op Mrgn n/a 27.1%
ROCE n/a  
Latest F'cast
P/E 39.6 8.3
PEG n/a 10.7
Pr/Revenue 9.6 1.7
Pr/Book 5.3  
Latest F'cast
Revenue n/a 324.7%
PBT 7.7% 525.4%
EPS n/a 0.8%
DPS n/a 301.3%

GSK Fundamentals

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-19 33,754.00 6,221.00 123.90p 17.9 4.5 +4% 80.00p 3.6%
31-Dec-20 34,099.00 6,968.00 115.90p 14.5 n/a -6% 80.00p 4.8%
31-Dec-21 24,696.00 3,599.00 90.56p 22.2 n/a -22% 80.00p 4.0%
31-Dec-22 29,324.00 5,628.00 139.70p 10.3 0.2 +54% 44.00p 3.1%
31-Dec-23 30,328.00 6,064.00 155.10p 9.4 0.9 +11% 42.00p 2.9%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

GSK Forecasts

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-24 31,269.42 8,474.23 156.31p 8.3 10.6 +1% 60.19p 0.0%
31-Dec-25 32,477.91 9,385.04 168.80p 7.7 1.0 +8% 64.01p 0.0%
31-Dec-26 34,260.71 10,405.81 186.64p 7.0 0.7 +11% 68.62p 0.0%

Copyright © 2024 FactSet Research Systems Inc. All rights reserved.

GSK Company Announcements

Director/PDMR Shareholding 19-Nov-2024 15:30 RNS
GLISTEN Trial of Linerixibat Meets Endpoint 19-Nov-2024 07:00 RNS
GSK announces overall survival results for Blenrep 14-Nov-2024 07:00 RNS

GSK ShareCast News

GSK's linerixibat meets primary endpoint 19-Nov-2024 ShareCast
London close: Stocks end turbulent week in the red 15-Nov-2024 ShareCast
GSK's Blenrep shows strong survival benefit in m... 14-Nov-2024 ShareCast

GSK Top Newspaper Links

GlaxoSmithKline scraps sale of old drugs 05-Dec-2014 Telegraph
Glaxo sharpens axe to save £1bn as insurers and ... 01-Dec-2014 The Independent
GSK to cut hundreds of US jobs 01-Dec-2014 Telegraph

Latest GSK Director Deals

Traded Action Notifier PriceAmountValue
15-Nov-24 Buy Hal Barron 2,643.57p 3,447 £91,126.43
11-Nov-24 Transfer From Julie Brown 0.000p 8 £0.00
11-Nov-24 Buy Julie Brown 1,398.93p 8 £111.91

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

 

GSK Market Data

Currency UK Pounds
Share Price 1,311.50p
Change Today 11.50p
% Change 0.88 %
52 Week High 1,812.50p
52 Week Low 1,300.00p
Volume 1,231,408
Shares Issued 4,145.10m
Market Cap £54,363m
Beta 0.56
RiskGrade 129

GSK Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
48.16% below the market average48.16% below the market average48.16% below the market average48.16% below the market average48.16% below the market average
16.00% above the sector average16.00% above the sector average16.00% above the sector average16.00% above the sector average16.00% above the sector average
Price Trend
36.75% below the market average36.75% below the market average36.75% below the market average36.75% below the market average36.75% below the market average
18.37% above the sector average18.37% above the sector average18.37% above the sector average18.37% above the sector average18.37% above the sector average
Income
47.15% above the market average47.15% above the market average47.15% above the market average47.15% above the market average47.15% above the market average
100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average
Growth
5.4% below the market average5.4% below the market average5.4% below the market average5.4% below the market average5.4% below the market average
23.53% above the sector average23.53% above the sector average23.53% above the sector average23.53% above the sector average23.53% above the sector average

What The Brokers Say

Strong Buy 7
Buy 4
Neutral 11
Sell 2
Strong Sell 0
Total 24
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

GSK Dividends

  Latest Previous
  Q3 Q2
Ex-Div 15-Nov-24 15-Aug-24
Paid 09-Jan-25 10-Oct-24
Amount 15.00p 15.00p

Trades for 21-Nov-2024

Time Volume / Share Price
12:47 192 @ 1,311.50p
12:47 380 @ 1,311.50p
12:47 62 @ 1,311.50p
12:46 72 @ 1,311.78p
12:46 292 @ 1,311.50p

GSK Key Personnel

CEO Emma Walmsley

Top of Page